BioMarin Pharmaceutical Given Average Rating of “Buy” by Brokerages (NASDAQ:BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN) has been given a consensus recommendation of “Buy” by the seventeen analysts that are covering the stock, AmericanBankingNews.com reports. Eight investment analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $82.46.
In other BioMarin Pharmaceutical news, EVP Henry J. Fuchs sold 10,000 shares of the company’s stock on the open market in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $65.00, for a total transaction of $650,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
BMRN has been the subject of a number of recent research reports. Analysts at Nomura raised their price target on shares of BioMarin Pharmaceutical from $77.00 to $82.00 in a research note on Thursday, July 31st. They now have a “neutral” rating on the stock. Analysts at Credit Suisse upgraded shares of BioMarin Pharmaceutical from a “neutral” rating to an “outperform” rating in a research note on Monday, June 9th. They now have a $73.00 price target on the stock, up previously from $61.74.
BioMarin Pharmaceutical (NASDAQ:BMRN) traded up 0.15% during mid-day trading on Friday, hitting $67.77. The stock had a trading volume of 116,704 shares. BioMarin Pharmaceutical has a 1-year low of $55.04 and a 1-year high of $84.25. The stock has a 50-day moving average of $61. and a 200-day moving average of $65.30. The company’s market cap is $9.970 billion.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Wednesday, July 30th. The company reported ($0.23) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.41) by $0.18. The company had revenue of $191.70 million for the quarter, compared to the consensus estimate of $159.70 million. During the same quarter last year, the company posted ($0.16) earnings per share. BioMarin Pharmaceutical’s revenue was up 40.1% compared to the same quarter last year. On average, analysts predict that BioMarin Pharmaceutical will post $-1.23 earnings per share for the current fiscal year.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Receive News & Ratings for BioMarin Pharmaceutical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.